Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

Phase II trial begins for ISS therapy for asthma

Feb. 13, 2003

8-Arylquinolines with PDE4-inhibitory activity in Merck pipeline

Feb. 13, 2003

AstraZeneca completes MRP in E.U. for Symbicort Turbuhaler in COPD

Feb. 12, 2003

Beneficial effects for SAR-943 on inflammation and remodeling in murine asthma model

Feb. 11, 2003

Revotar and Texas Biotechnology amend bimosiamose license agreement

Feb. 11, 2003

Recent patent reports novel PDE4 inhibitors with utility in asthma and other disorders

Feb. 10, 2003

Almirall Prodesfarma claims adenosine A2B antagonists for use in asthma and other disorders

Feb. 7, 2003

Phase III study initiated for HL-10 in ALI/ARDS

Feb. 6, 2003

Applied Genetic Technologies' A1AD treatment granted orphan drug status

Feb. 5, 2003

Grelan researchers prepare and test new naphthyridine-based PDE4 inhibitors

Feb. 3, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.